终末期肾衰竭患者全髋关节置换术的并发症与再入院发生率
基于5% Medicare数据库2007至2016年55,297例初次全髋关节置换术患者,分为透析组、肾移植组和无肾问题组。透析组5年死亡率62.6%、脱位7.6%、假体周围感染7%,90天再入院率透析组55%、移植组43%,均显著高于无肾问题组的30%。
要点
- 透析组5年死亡率为62.6%,移植组37.3%,无肾问题组15.0%。
- 透析组脱位7.6%和假体周围感染7%均显著高于其他组(P < .001)。
- 透析组和移植组90天再入院风险分别为55%和43%,显著高于无肾问题组的30%(P < .001)。
核心结论
- 透析患者行全髋关节置换术后假体周围感染(7%)、脱位(7.6%)、翻修和90天死亡率风险增加。
- 透析和移植患者均为高风险群体,90天再入院发生率分别显著升高至55%和43%,使其纳入捆绑支付模式具有挑战性。
研究设计与样本
- 共纳入55,297例初次全髋关节置换术患者,分为透析组(无移植)、肾移植组和无肾问题组。
- 采用多因素Cox回归分析评估患者和医院特征对校正后并发症风险的影响。
主要发现
- 5年死亡率:透析组62.6%,肾移植组37.3%,无肾问题组15.0%。
- 透析组脱位发生率7.6%、假体周围感染发生率7%,均显著高于其他组(P < .001)。
- 肾各组间静脉血栓栓塞性疾病(所有时间点)和翻修(除90天外所有时间点)无显著差异。
- 90天再入院风险:透析组55%、移植组43%,均显著高于无肾问题组的30%(P < .001)。
关键数值与推荐
- 透析组5年死亡率为62.6%,肾移植组为37.3%,无肾问题组为15.0%。
- 透析组脱位发生率为7.6%,假体周围感染发生率为7%(P < .001)。
- 90天再入院率:透析组55%,肾移植组43%,无肾问题组30%(P < .001)。
临床怎么用
- 对透析和肾移植患者行全髋关节置换术前应充分告知其高并发症和高再入院风险。
- 透析患者术后需重点监测假体周围感染和脱位,并关注90天内再入院风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The number of patients who have end-stage renal disease undergoing primary total hip arthroplasty (THA) has increased over the past decade. The purpose of this study is to evaluate mortality, complications, and 90-day readmission incidences in patients who have end-stage renal disease undergoing THA. METHODS: Patients who had a primary THA between January 1, 2007, and December 31, 2016, were identified from the 5% Medicare database. A total of 55,297 THA patients were stratified into 3 groups: renal dialysis (without transplant), renal transplant, and those without such renal problems. Risk of readmissions, dislocations, periprosthetic joint infections (PJIs), venous thromboembolic diseases, and mortalities up to 5 years following primary THA was compared. Multivariate Cox regression analyses were used to evaluate the effect of patient and hospital characteristics on the adjusted complication risks. RESULTS: Mortalities at 5 years was 62.6% in the renal dialysis group, 37.3% in the renal transplant group, compared to 15.0% in the nonrenal group. Dislocations (7.6%) and PJIs (7%) were significantly higher in the dialysis group (P < .001). No significant differences in venous thromboembolic diseases (all timepoints) and revisions (all timepoints except at 90 days) between the renal groups were observed. The 90-day readmission risks were significantly greater in both the dialysis (55%) and transplant (43%) groups compared to the nonrenal cohort (30%) (P < .001). CONCLUSION: Renal dialysis patients undergoing THA are at increased risk of PJIs (7%), dislocations (7.6%), revisions, and mortalities at 90 days compared to transplant and nonrenal patients. Both dialysis and transplant patients are high-risk groups with significantly increased 90-day readmission incidences of 55% and 43%, respectively, which makes their inclusion into a bundled payment model challenging.
引用
- Malkani JA, Heimroth JC, Ong KL, et al. Complications and Readmission Incidence Following Total Hip Arthroplasty in Patients Who Have End-Stage Renal Failure. J Arthroplasty. 2019. PMID: 31784363. doi:10.1016/j.arth.2019.10.042
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。